Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments

Head and Neck Cancers

(2017) David G. Pfister et al.   Journal of the National Comprehensive Cancer Network

Dose-dependent response of tumor vasculature to radiation therapy in combination with Sunitinib depicted by three-dimensional high-frequency power Doppler ultrasound

(2013) Ahmed El Kaffas et al.   ANGIOGENESIS

The Hallmarks of Cancer and the Radiation Oncologist: Updating the 5Rs of Radiobiology

(2013) J.S. Good et al.   CLINICAL ONCOLOGY

New Molecular Targets in the Treatment of NSCLC

(2013) Clorinda Schettino et al.   CURRENT PHARMACEUTICAL DESIGN

A Phase 3 Trial of Whole Brain Radiation Therapy and Stereotactic Radiosurgery Alone Versus WBRT and SRS With Temozolomide or Erlotinib for Non-Small Cell Lung Cancer and 1 to 3 Brain Metastases: Radiation Therapy Oncology Group 0320

(2013) Paul W. Sperduto et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Role of Epidermal Growth Factor Receptor Inhibitors in Epidermal Growth Factor Receptor Wild-Type Non–Small-Cell Lung Cancer

(2013) Scott A. Laurie et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial

(2013) Renato G. Martins et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrating the integrin response

(2013) Kirsty Minton   NATURE REVIEWS MOLECULAR CELL BIOLOGY

The irradiated tumor microenvironment: role of tumor-associated macrophages in vascular recovery

(2013) Jeffery S. Russell et al.   Frontiers in Physiology

Mechanisms of Glioma-Associated Neovascularization

(2012) Matthew E. Hardee et al.   AMERICAN JOURNAL OF PATHOLOGY

β1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy

(2012) Iris Eke et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor angiogenesis and lymphangiogenesis: Tumor/endothelial crosstalk and cellular/microenvironmental signaling mechanisms

(2012) Fausto Gueths Gomes et al.   LIFE SCIENCES

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade

(2012) S Kasper et al.   ONCOGENE

Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia

(2012) S. J. Conley et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases

(2012) Hsin-Lun Lee et al.   Radiation Oncology

Human Papillomavirus as a Marker of the Natural History and Response to Therapy of Head and Neck Squamous Cell Carcinoma

(2012) Kie Kian Ang et al.   SEMINARS IN RADIATION ONCOLOGY

The impact of molecular targets in cancer drug development: major hurdles and future strategies

(2012) Alexandra Hebar et al.   Expert Review of Clinical Pharmacology

Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation

(2011) Carlos Mas-Moruno et al.   Anti-Cancer Agents in Medicinal Chemistry

Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy

(2011) Pek Keng Koh et al.   CANCER TREATMENT REVIEWS

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies

(2011) David A Reardon et al.   Future Oncology

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site

(2011) Pierre Blanchard et al.   RADIOTHERAPY AND ONCOLOGY

Monoclonal antibodies against EGFR in non-small cell lung cancer

(2010) Robert Pirker et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

CETUXIMAB: From Bench to Bedside

(2010) B. Vincenzi et al.   CURRENT CANCER DRUG TARGETS

Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?

(2010) Jean Bourhis et al.   EUROPEAN JOURNAL OF CANCER

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

(2010) Roger Stupp et al.   JOURNAL OF CLINICAL ONCOLOGY

HPV-associated head and neck cancer: a virus-related cancer epidemic

(2010) Shanthi Marur et al.   LANCET ONCOLOGY

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

(2010) Ulrich Gatzemeier et al.   LANCET ONCOLOGY

Targeting Epidermal Growth Factor Receptor-Associated Signaling Pathways in Non-Small Cell Lung Cancer Cells: Implication in Radiation Response

(2010) E. J. Choi et al.   MOLECULAR CANCER RESEARCH

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Integrins as therapeutic targets: lessons and opportunities

(2010) Dermot Cox et al.   NATURE REVIEWS DRUG DISCOVERY

Cetuximab May Inhibit Tumor Growth and Angiogenesis Induced by Ionizing Radiation: A Preclinical Rationale for Maintenance Treatment After Radiotherapy

(2010) G. Pueyo et al.   ONCOLOGIST

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

(2009) John M.L. Ebos et al.   CANCER CELL

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY

Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro

(2009) Gabriele D. Maurer et al.   NEURO-ONCOLOGY

Growth factors protect intestinal stem cells from radiation-induced apoptosis by suppressing PUMA through the PI3K/AKT/p53 axis

(2009) W Qiu et al.   ONCOGENE

Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel

(2008) Gabriela Kornek et al.   CURRENT PHARMACEUTICAL DESIGN

The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials

(2008) Nicolas Magné et al.   EUROPEAN JOURNAL OF CANCER

Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012

(2008) Tobey J. MacDonald et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells

(2008) Dhara N. Amin et al.   MICROVASCULAR RESEARCH

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

(2008) Jan B. Vermorken et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY